SPRY

SEC source: 0001209191-20-062387 · doc4.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner

ORBIMED CAPITAL LLC · CIK 0001157524 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By OrbiMed Private Investments VI, LP

Disclosed balance after: 3,970,160

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · shares: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F4 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner to OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI. Both GP VI and OrbiMed Advisors may be deemed to directly or indirectly, including by reason of their mutual affiliation, to be beneficial owners of the shares held by OPI VI. OrbiMed Advisors exercise investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein and Sven H. Borho, each of whom disclaims beneficial ownership of the shares of OPI VI.

F3 · ownership.nature: This report on Form 4 is jointly filed by GP VI, OrbiMed Advisors, and OrbiMed Capital LLC ("OrbiMed Capital"). Each of the Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Peter Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001209191-20-062387 · doc4.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner

ORBIMED CAPITAL LLC · CIK 0001157524 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By OrbiMed Private Investments VI, LP

Disclosed balance after: 507,423

F1 · kind: The shares were purchased in the Issuer's initial public offering.

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner to OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI. Both GP VI and OrbiMed Advisors may be deemed to directly or indirectly, including by reason of their mutual affiliation, to be beneficial owners of the shares held by OPI VI. OrbiMed Advisors exercise investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein and Sven H. Borho, each of whom disclaims beneficial ownership of the shares of OPI VI.

F3 · ownership.nature: This report on Form 4 is jointly filed by GP VI, OrbiMed Advisors, and OrbiMed Capital LLC ("OrbiMed Capital"). Each of the Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Peter Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001548538-20-000027 · edgar.xml · derivative · entry 9

Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner

U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner

U.S. Venture Partners XII-A, L.P. · CIK 0001754875 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S. Venture Partners XII-A, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 14,677 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

SEC source: 0001548538-20-000027 · edgar.xml · derivative · entry 8

Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner

U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner

U.S. Venture Partners XII-A, L.P. · CIK 0001754875 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S. Venture Partners XII, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 289,198 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

SEC source: 0001548538-20-000027 · edgar.xml · derivative · entry 7

Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner

U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner

U.S. Venture Partners XII-A, L.P. · CIK 0001754875 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S. Venture Partners XII-A, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 90,335 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

SEC source: 0001548538-20-000027 · edgar.xml · derivative · entry 6

Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner

U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner

U.S. Venture Partners XII-A, L.P. · CIK 0001754875 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S. Venture Partners XII, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 1,779,969 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

SEC source: 0001548538-20-000027 · edgar.xml · nonDerivative · entry 5

Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner

U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner

U.S. Venture Partners XII-A, L.P. · CIK 0001754875 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by Tansey

Disclosed balance after: 47,619

F1 · kind: The shares were purchased in the Issuer's initial public offering.

SEC source: 0001548538-20-000027 · edgar.xml · nonDerivative · entry 4

Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner

U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner

U.S. Venture Partners XII-A, L.P. · CIK 0001754875 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S. Venture Partners XII-A, L.P.

Disclosed balance after: 105,012

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

SEC source: 0001548538-20-000027 · edgar.xml · nonDerivative · entry 3

Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner

U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner

U.S. Venture Partners XII-A, L.P. · CIK 0001754875 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S. Venture Partners XII-A, L.P.

Disclosed balance after: 90,335

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

SEC source: 0001548538-20-000027 · edgar.xml · nonDerivative · entry 2

Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner

U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner

U.S. Venture Partners XII-A, L.P. · CIK 0001754875 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S. Venture Partners XII, L.P.

Disclosed balance after: 2,069,167

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

SEC source: 0001548538-20-000027 · edgar.xml · nonDerivative · entry 1

Presidio Management Group XII, L.L.C. · CIK 0001734820 · 10% owner

U.S. Venture Partners XII, L.P. · CIK 0001734819 · 10% owner

U.S. Venture Partners XII-A, L.P. · CIK 0001754875 · 10% owner

Tansey Casey M · CIK 0001474322 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S. Venture Partners XII, L.P.

Disclosed balance after: 1,779,969

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-20-062404 · doc4.xml · nonDerivative · entry 1

CAPPS VICKIE L · CIK 0001248190 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,576

F1 · kind: The shares were purchased in the Issuer's initial public offering.

SEC source: 0001209191-20-062401 · doc4.xml · nonDerivative · entry 1

Hawkinson Russ · CIK 0001831807 · Sr. Vice President of Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 238

F1 · kind: The shares were purchased in the Issuer's initial public offering.

SEC source: 0001209191-20-062397 · doc4.xml · nonDerivative · entry 1

Piazza Jonathan · CIK 0001831967 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,904

F1 · kind: The shares were purchased in the Issuer's initial public offering.

SEC source: 0001209191-20-062394 · doc4.xml · derivative · entry 5

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Nextech VI Oncology SCSp

Disclosed balance after: 0

Underlying: Common Stock · 425,063 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F3 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F3 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · ownership.nature: Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-20-062394 · doc4.xml · derivative · entry 4

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Nextech VI Oncology SCSp

Disclosed balance after: 0

Underlying: Common Stock · 1,246,870 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F3 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F3 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · ownership.nature: Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-20-062394 · doc4.xml · nonDerivative · entry 3

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Nextech VI Oncology SCSp

Disclosed balance after: 1,910,029

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · shares: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F3 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · ownership.nature: Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-20-062394 · doc4.xml · nonDerivative · entry 2

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Nextech VI Oncology SCSp

Disclosed balance after: 1,484,966

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · shares: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F3 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · ownership.nature: Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-20-062394 · doc4.xml · nonDerivative · entry 1

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Nextech VI Oncology SCSp

Disclosed balance after: 238,096

F1 · kind: The shares were purchased in the Issuer's initial public offering.

F2 · ownership.nature: Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-20-062391 · doc4.xml · derivative · entry 9

ROOT JONATHAN D · CIK 0001225480 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S.VenturePartners XII-A,L.P.

Disclosed balance after: 0

Underlying: Common Stock · 14,677 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. (PMG XII), the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, USVP XII), has sole voting and dispositive power with respect to the shares held by USVP XII. The reporting person is a managing member of PMG XII, and shares voting and dispositive power with respect to the shares held by USVP XII. The reporting person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.

SEC source: 0001209191-20-062391 · doc4.xml · derivative · entry 8

ROOT JONATHAN D · CIK 0001225480 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S VenturePartners XII,L.P.

Disclosed balance after: 0

Underlying: Common Stock · 289,198 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. (PMG XII), the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, USVP XII), has sole voting and dispositive power with respect to the shares held by USVP XII. The reporting person is a managing member of PMG XII, and shares voting and dispositive power with respect to the shares held by USVP XII. The reporting person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.

SEC source: 0001209191-20-062391 · doc4.xml · derivative · entry 7

ROOT JONATHAN D · CIK 0001225480 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S.VenturePartners XII-A,L.P.

Disclosed balance after: 0

Underlying: Common Stock · 90,335 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. (PMG XII), the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, USVP XII), has sole voting and dispositive power with respect to the shares held by USVP XII. The reporting person is a managing member of PMG XII, and shares voting and dispositive power with respect to the shares held by USVP XII. The reporting person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.

SEC source: 0001209191-20-062391 · doc4.xml · derivative · entry 6

ROOT JONATHAN D · CIK 0001225480 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S VenturePartners XII,L.P.

Disclosed balance after: 0

Underlying: Common Stock · 1,779,969 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. (PMG XII), the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, USVP XII), has sole voting and dispositive power with respect to the shares held by USVP XII. The reporting person is a managing member of PMG XII, and shares voting and dispositive power with respect to the shares held by USVP XII. The reporting person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.

SEC source: 0001209191-20-062391 · doc4.xml · nonDerivative · entry 5

ROOT JONATHAN D · CIK 0001225480 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S.VenturePartners XII-A,L.P.

Disclosed balance after: 105,012

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. (PMG XII), the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, USVP XII), has sole voting and dispositive power with respect to the shares held by USVP XII. The reporting person is a managing member of PMG XII, and shares voting and dispositive power with respect to the shares held by USVP XII. The reporting person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.

SEC source: 0001209191-20-062391 · doc4.xml · nonDerivative · entry 4

ROOT JONATHAN D · CIK 0001225480 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S.VenturePartners XII-A,L.P.

Disclosed balance after: 90,335

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. (PMG XII), the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, USVP XII), has sole voting and dispositive power with respect to the shares held by USVP XII. The reporting person is a managing member of PMG XII, and shares voting and dispositive power with respect to the shares held by USVP XII. The reporting person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.

SEC source: 0001209191-20-062391 · doc4.xml · nonDerivative · entry 3

ROOT JONATHAN D · CIK 0001225480 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S VenturePartners XII,L.P.

Disclosed balance after: 2,069,167

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. (PMG XII), the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, USVP XII), has sole voting and dispositive power with respect to the shares held by USVP XII. The reporting person is a managing member of PMG XII, and shares voting and dispositive power with respect to the shares held by USVP XII. The reporting person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.

SEC source: 0001209191-20-062391 · doc4.xml · nonDerivative · entry 2

ROOT JONATHAN D · CIK 0001225480 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By U.S VenturePartners XII,L.P.

Disclosed balance after: 1,779,969

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F3 · ownership.nature: Presidio Management Group XII, L.L.C. (PMG XII), the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, USVP XII), has sole voting and dispositive power with respect to the shares held by USVP XII. The reporting person is a managing member of PMG XII, and shares voting and dispositive power with respect to the shares held by USVP XII. The reporting person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.

SEC source: 0001209191-20-062391 · doc4.xml · nonDerivative · entry 1

ROOT JONATHAN D · CIK 0001225480 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,238

F1 · kind: The shares were purchased in the Issuer's initial public offering.

SEC source: 0001209191-20-062390 · doc4.xml · derivative · entry 9

Thompson Peter A. · CIK 0001357522 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By OrbiMed Private Investments VI, LP

Disclosed balance after: 0

Underlying: Common Stock · 1,055,287 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F4 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F4 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner to OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI. Both GP VI and OrbiMed Advisors may be deemed to directly or indirectly, including by reason of their mutual affiliation, to be beneficial owners of the shares held by OPI VI. OrbiMed Advisors exercise investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein and Sven H. Borho, each of whom disclaims beneficial ownership of the shares of OPI VI.

F3 · ownership.nature: The Reporting Person is the designated representative of OrbiMed Advisors on the Issuer's Board of Directors. The reportable securities are owned indirectly by OPI VI. GP VI is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-20-062390 · doc4.xml · derivative · entry 8

Thompson Peter A. · CIK 0001357522 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By OrbiMed Private Investments VI, LP

Disclosed balance after: 0

Underlying: Common Stock · 2,493,741 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F4 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F4 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner to OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI. Both GP VI and OrbiMed Advisors may be deemed to directly or indirectly, including by reason of their mutual affiliation, to be beneficial owners of the shares held by OPI VI. OrbiMed Advisors exercise investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein and Sven H. Borho, each of whom disclaims beneficial ownership of the shares of OPI VI.

F3 · ownership.nature: The Reporting Person is the designated representative of OrbiMed Advisors on the Issuer's Board of Directors. The reportable securities are owned indirectly by OPI VI. GP VI is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-20-062390 · doc4.xml · derivative · entry 7

Thompson Peter A. · CIK 0001357522 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By OrbiMed Private Investments VI, LP

Disclosed balance after: 0

Underlying: Common Stock · 3,462,737 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F4 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F4 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner to OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI. Both GP VI and OrbiMed Advisors may be deemed to directly or indirectly, including by reason of their mutual affiliation, to be beneficial owners of the shares held by OPI VI. OrbiMed Advisors exercise investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein and Sven H. Borho, each of whom disclaims beneficial ownership of the shares of OPI VI.

F3 · ownership.nature: The Reporting Person is the designated representative of OrbiMed Advisors on the Issuer's Board of Directors. The reportable securities are owned indirectly by OPI VI. GP VI is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-20-062390 · doc4.xml · nonDerivative · entry 5

Thompson Peter A. · CIK 0001357522 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By OrbiMed Partners Master Fund Limited

Disclosed balance after: 952,377

F1 · kind: The shares were purchased in the Issuer's initial public offering.

F5 · ownership.nature: These securities are held of record by OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital LLC ("OrbiMed Capital") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein and Sven H. Borho, each of whom disclaims beneficial ownership of the shares held by OPM.

SEC source: 0001209191-20-062390 · doc4.xml · nonDerivative · entry 4

Thompson Peter A. · CIK 0001357522 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By OrbiMed Private Investments VI, LP

Disclosed balance after: 7,519,188

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · shares: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F4 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner to OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI. Both GP VI and OrbiMed Advisors may be deemed to directly or indirectly, including by reason of their mutual affiliation, to be beneficial owners of the shares held by OPI VI. OrbiMed Advisors exercise investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein and Sven H. Borho, each of whom disclaims beneficial ownership of the shares of OPI VI.

F3 · ownership.nature: The Reporting Person is the designated representative of OrbiMed Advisors on the Issuer's Board of Directors. The reportable securities are owned indirectly by OPI VI. GP VI is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-20-062390 · doc4.xml · nonDerivative · entry 3

Thompson Peter A. · CIK 0001357522 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By OrbiMed Private Investments VI, LP

Disclosed balance after: 6,463,901

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · shares: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F4 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner to OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI. Both GP VI and OrbiMed Advisors may be deemed to directly or indirectly, including by reason of their mutual affiliation, to be beneficial owners of the shares held by OPI VI. OrbiMed Advisors exercise investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein and Sven H. Borho, each of whom disclaims beneficial ownership of the shares of OPI VI.

F3 · ownership.nature: The Reporting Person is the designated representative of OrbiMed Advisors on the Issuer's Board of Directors. The reportable securities are owned indirectly by OPI VI. GP VI is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-20-062390 · doc4.xml · nonDerivative · entry 2

Thompson Peter A. · CIK 0001357522 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By OrbiMed Private Investments VI, LP

Disclosed balance after: 3,970,160

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · shares: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F4 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner to OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI. Both GP VI and OrbiMed Advisors may be deemed to directly or indirectly, including by reason of their mutual affiliation, to be beneficial owners of the shares held by OPI VI. OrbiMed Advisors exercise investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein and Sven H. Borho, each of whom disclaims beneficial ownership of the shares of OPI VI.

F3 · ownership.nature: The Reporting Person is the designated representative of OrbiMed Advisors on the Issuer's Board of Directors. The reportable securities are owned indirectly by OPI VI. GP VI is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-20-062390 · doc4.xml · nonDerivative · entry 1

Thompson Peter A. · CIK 0001357522 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By OrbiMed Private Investments VI, LP

Disclosed balance after: 507,423

F1 · kind: The shares were purchased in the Issuer's initial public offering.

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner to OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI. Both GP VI and OrbiMed Advisors may be deemed to directly or indirectly, including by reason of their mutual affiliation, to be beneficial owners of the shares held by OPI VI. OrbiMed Advisors exercise investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein and Sven H. Borho, each of whom disclaims beneficial ownership of the shares of OPI VI.

F3 · ownership.nature: The Reporting Person is the designated representative of OrbiMed Advisors on the Issuer's Board of Directors. The reportable securities are owned indirectly by OPI VI. GP VI is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.

SEC source: 0001722024-20-000020 · wf-form4_160746339873406.xml · derivative · entry 3

Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 314,664 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date.

F2 · price: Not applicable.

F1 · derivative.exercise_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date.

F1 · derivative.expiration_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date.

SEC source: 0001722024-20-000020 · wf-form4_160746339873406.xml · derivative · entry 2

Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 384,748 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date.

F2 · price: Not applicable.

F1 · derivative.exercise_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date.

F1 · derivative.expiration_date: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date.

SEC source: 0001722024-20-000020 · wf-form4_160746339873406.xml · nonDerivative · entry 1

Alexandria Venture Investments, LLC · CIK 0001722024 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 699,412

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 3.713 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on December 3, 2020, for no additional consideration. The shares had no expiration date.

SEC source: 0001209191-22-012878 · doc4a.xml · nonDerivative · entry 1

Hawkinson Russ · CIK 0001831807 · Sr. Vice President of Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200

F1 · kind: The shares were purchased in the Issuer's initial public offering.

F2 · shares: On December 8, 2020, the reporting person filed a Form 4 in which he inadvertently reported a purchase of 238 shares of the issuer's common stock. In fact, as reported in this amendment, the reporting person purchased 200 shares of the issuer's common stock.

SEC source: 0001209191-20-062055 · doc4.xml · derivative · entry 1

Thompson Peter A. · CIK 0001357522 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,270

Underlying: Common Stock · 38,270 shares

Expires 2030-12-02

F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 36 months following December 3, 2020.

F2 · ownership.direct: The Reporting Person is the designated representative of OrbiMed Advisors LLC ("OrbiMed Advisors") on the Issuer's Board of Directors. The reportable securities are owned indirectly by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-20-062054 · doc4.xml · derivative · entry 1

Odegard Valerie · CIK 0001832432 · President and CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 364,904

Underlying: Common Stock · 364,904 shares

Expires 2030-12-02

F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 48 months following December 3, 2020.

SEC source: 0001209191-20-062053 · doc4.xml · derivative · entry 1

Shawver Laura · CIK 0001551891 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 562,631

Underlying: Common Stock · 562,631 shares

Expires 2030-12-02

F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 48 months following December 3, 2020.

SEC source: 0001209191-20-062051 · doc4.xml · derivative · entry 1

ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,270

Underlying: Common Stock · 38,270 shares

Expires 2030-12-02

F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 36 months following December 3, 2020.

SEC source: 0001209191-20-062050 · doc4.xml · derivative · entry 1

Powell Andrew Kenneth William · CIK 0001304113 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,009

Underlying: Common Stock · 21,009 shares

Expires 2030-12-02

F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 36 months following December 3, 2020.

SEC source: 0001209191-20-062049 · doc4.xml · derivative · entry 1

Piazza Jonathan · CIK 0001831967 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,730

Underlying: Common Stock · 74,730 shares

Expires 2030-12-02

F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 48 months following December 3, 2020.

SEC source: 0001209191-20-062048 · doc4.xml · derivative · entry 1

Islam Saqib · CIK 0001575408 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,753

Underlying: Common Stock · 69,753 shares

Expires 2030-12-02

F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 36 months following December 3, 2020.

SEC source: 0001209191-20-062047 · doc4.xml · derivative · entry 1

Hunder Naomi · CIK 0001832170 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 231,071

Underlying: Common Stock · 231,071 shares

Expires 2030-12-02

F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 48 months following December 3, 2020.

SEC source: 0001209191-20-062046 · doc4.xml · derivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,251

Underlying: Common Stock · 73,251 shares

Expires 2030-12-02

F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 36 months following December 3, 2020.

SEC source: 0001209191-20-062045 · doc4.xml · derivative · entry 1

Hawkinson Russ · CIK 0001831807 · Sr. Vice President of Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,038

Underlying: Common Stock · 102,038 shares

Expires 2030-12-02

F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 48 months following December 3, 2020.